Quarterly ResultAug 6, 2026, 04:22 PM
Definium Therapeutics Reports Positive Phase 3 MDD Results; Q2 Net Loss $159M
AI Summary
Definium Therapeutics announced positive topline results from its Phase 3 Emerge study of DT120 ODT in major depressive disorder, demonstrating rapid and durable efficacy. The company reported a Q2 2026 net loss of $159.0 million, significantly impacted by a non-cash warrant liability adjustment. Definium also completed a public offering raising $805 million in gross proceeds, boosting its cash, cash equivalents, and investments to approximately $1.1 billion, sufficient to fund operations into 2030. Upcoming Phase 3 results for DT120 ODT in generalized anxiety disorder are anticipated in August and September 2026.
Key Highlights
- Positive Phase 3 Emerge study (MDD) results for DT120 ODT announced.
- DT120 ODT showed 8.1-point MADRS improvement at Week 6 (p<0.0001).
- Cash, cash equivalents, and investments totaled $1.1 billion as of June 30, 2026.
- Completed public offering generated $805 million in gross proceeds.
- Net loss for Q2 2026 was $159.0 million, up from $42.7 million in Q2 2025.
- R&D expenses increased to $48.7 million in Q2 2026 from $29.8 million in Q2 2025.
- G&A expenses rose to $26.4 million in Q2 2026 from $11.1 million in Q2 2025.
- Phase 3 GAD study results (Voyage) expected week of August 10, 2026.
Price Impact
More from DFTX